Free tool
FAERS Monitor: Livdelzi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217899 or its brand name (Livdelzi, Seladelpar Lysine). Reports on generic versions are filed under their own applications.
Reports
276
Serious
101
37% of reports
Hospitalization
17
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective26
- blood alkaline phosphatase increased24
- aspartate aminotransferase increased22
- headache22
- alanine aminotransferase increased20
- pruritus20
- dizziness18
- fatigue15
- nausea14
- diarrhoea12
- abdominal distension11
- abdominal pain11
- hepatic enzyme increased10
- abdominal pain upper9
- gamma-glutamyltransferase increased8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 8 |
| 2025 | 157 |
| 2026 | 111 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,883 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood alkaline phosphatase increasedSignal | 24 | 73.8 | 50.3 | 1,651 |
| aspartate aminotransferase increasedSignal | 22 | 31.6 | 21.1 | 623 |
| gamma-glutamyltransferase increasedSignal | 8 | 27.5 | 13.9 | 179 |
| alanine aminotransferase increasedSignal | 20 | 24.8 | 16.3 | 435 |
| hepatic enzyme increasedSignal | 10 | 11.2 | 6.1 | 83 |
| abdominal distensionSignal | 11 | 8.0 | 4.5 | 61 |
| pruritusSignal | 20 | 4.0 | 2.6 | 42 |
| abdominal painSignal | 11 | 3.6 | 2.0 | 18 |
| abdominal pain upperSignal | 9 | 3.3 | 1.8 | 13 |
| dizzinessSignal | 18 | 2.8 | 1.8 | 19 |
| headacheSignal | 22 | 2.7 | 1.8 | 22 |
| drug ineffective | 26 | 1.5 | 1.0 | 4 |
| fatigue | 15 | 1.5 | 0.9 | 2 |
| diarrhoea | 12 | 1.4 | 0.8 | 1 |
| nausea | 14 | 1.3 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.